Cipla, a prominent Indian pharmaceutical company, announced that it has entered into a licensing agreement with Novartis Pharma AG (Switzerland) to produce and market the Galvus range, which is used in the treatment of type 2 diabetes, effective from January 1, 2026.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
According to the regulatory filing, Cipla has signed a perpetual license agreement to manufacture and market Galvus and Galvus combination brands. The drug firm believes that this partnership will enhance its standing in the diabetes category and reinforce its position as one of the major players in the Indian market. The agreement is contingent upon the fulfillment of certain preconditions, as stated by Cipla. The Galvus brand is a prominent name in the Dipeptidyl Peptidase-4 (DPP4) space and a major player in the oral diabetic medication category, according to the drug firm. On the Bombay Stock Exchange (BSE), Cipla’s shares rose by 1.02 percent to close at Rs 901.85 apiece.
You may also read this:
IIT-Bombay and UIDAI join hands to develop touchless biometric system
Did you know that the festival of Holi is celebrated in many different ways across…
Did you know that kidney beans are one of the most widely eaten beans in…
Did you know that every country has a special city where important decisions are made…
Astep toward wildlife conservation and public safety. The Deputy CM of Andhra Pradesh Pawan Kalyan…
Jio Platforms Limited has appointed telecom industry veteran Dan Bailey as its new President to…
The Top 10 most popular websites of 2026 show how the internet continues to evolve…